LIST OF TABLES

Table No.	Title	Page No.
2.1	Endogenous angiogenesis factors	16
2.2	Anti-angiogenic agents	33
2.3	Natural Health Products With Potential Direct and Indirect Antiangiogenic Activity	41
4.1	Solubility of ET and QD at RT	92
4.2a	Calibration curve of ET in Acetonitrile	94
4.2b	Calibration curve of QD in Acetonitrile	96
4.3a	Analytical parameters for estimation of ET in acetonitrile	97
4.3b	Analytical parameters for estimation of QD in acetonitrile	97
4.4a	Evaluation of accuracy and precision of estimation method of ET in acetonitrile	97
4.4b	Evaluation of accuracy and precision of estimation method of QD in acetonitrile	97
4.5a	Calibration curve of ET in pH 7.4 phosphate buffer	100
4.5b	Calibration curve of QD in pH 7.4 phosphate buffer	102
4.6a	Analytical parameters for estimation of ET in pH 7.4 phosphate buffer	103
4.6b	Analytical parameters for estimation of QD in pH 7.4 phosphate buffer	103
4.7a	Evaluation of accuracy and precision of estimation method of ET in pH 7.4 phosphate buffer	103
4.7b	Evaluation of accuracy and precision of estimation method of QD in pH 7.4 phosphate buffer	103
5.1	Optimization of various parameters for ETN formulations	114
5.2	Optimization of various parameters for QDN formulations	115
5.3	Zeta potentials of optimized nanoparticle formulations	121
5.4	Effect of storage conditions on the particle size of ETN and QDN	126
5.5	Effect of storage conditions on the drug content of ETN and QDN	126
6.1	% Cumulative drug release in pH7.4 phosphate buffer	136

Table No.	Title	Page No.
6.2	Correlation Co-efficients for different dissolution models	137
6.3	Disolution parameters for drug release from nanoparicles for Korsmeyer-Peppas Kinetics	137
6.4	IC 50 values for various treatments for cell line A549	138
6.5	A549 Cell viabilities in % at 24 hrs for various treatments	139
6.6	A549 Cell viabilities in % at 48 hrs for various treatments	139
6.7	A549 Cell viabilities in % at 72 hrs for various treatments	140
7.1	Optimized conditions for ^{99m}Tc-labelling	148
7.2	*In vitro* serum stability of ^{99m}Tc-labeled complexes of ET, QD, ETN and QDN	148
7.3	% Injected dose of ^{99m}Tc-labeled complexes appearing in blood at various time points	149
7.4	Biodistribution of ^{99m}Tc-labeled complexes of ET and ETN at 2, 6 and 24 hrs	150
7.5	Biodistribution of ^{99m}Tc-labelled complexes of QD and QDN at 2, 6 and 24 hrs	150
7.6	Effect of various treatments on mean tumor volumes over 21 days period	155
7.7	Effect of various treatments on weight change in B16F10 melanoma bearing mice.....	159
7.8	Comparison of degree of angiogenesis for various treatments	162